Table 1.
Baseline demographic and clinical characteristics.
| Variable | Results | Number of patients evaluated |
|---|---|---|
| Age (years), mean ± SD (range) | 45.2 ± 17.9 (18–90) | 1681 |
| Females, n (%) | 592 (35.4) | 1670 |
| Males, n (%) | 1078 (64.6) | 1670 |
| Age at diagnosis (years), mean ± SD | 33.8 ± 15.7 | 1682 |
| Disease duration (years), mean ± SD | 14.9 ± 14.1 | 1682 |
| Time between treatment initiation and diagnosis (years), mean ± SD | 1.1 ± 6.6 | 1677 |
| Current smokers, n (%) | 263 (15.7) | 1678 |
| Ex-smoker, n (%) | 294 (20.8) | 1414 |
| Any allergy, n (%) | 665 (39.8) | 1671 |
| Any comorbidity, n (%) | 841 (50.4) | 1668 |
| Obesity, n (%) | 242 (14.5%) | 1668 |
| Rhinosinusitis, n (%) | 190 (11.4%) | 1668 |
| Rhinitis/conjunctivitis, n (%) | 313 (18.8%) | 1668 |
| Gastroesophageal reflux disease, n (%) | 149 (8.9%) | 1668 |
| Other comorbidities, n (%) | 268 (16.1) | 1668 |
| Predicted FEV1 (or personal best PEF value), n (%) | ||
| ≥80% | 1042 (62.3) | 1673 |
| <80% | 507 (30.3) | 1673 |
| <60% | 124 (7.4) | 1673 |
| Categories of asthma severity (2015 GINA), n (%) | ||
| Mild | 719 (42.9) | 1674 |
| Moderate | 780 (46.6) | 1674 |
| Severe | 175 (10.5) | 1674 |
| Level of asthma symptom control (2015 GINA) | ||
| Well controlled | 474 (28.2) | 1679 |
| aPartly controlled | 635 (37.8) | 1679 |
| aUncontrolled | 570 (33.9) | 1679 |
| Current treatments, n (%) | ||
| Only maintenance inhaler | 492 (29.6) | 1662 |
| Only rescue inhaler | 357 (21.5) | 1662 |
| Maintenance inhaler + rescue inhaler | 468 (28.2) | 1662 |
| Maintenance inhaler + oral treatment | 78 (4.7) | 1662 |
| Rescue inhaler + oral treatment | 40 (2.4) | 1662 |
| Maintenance inhaler + rescue inhaler + oral treatment | 206 (12.4) | 1662 |
| Monoclonal antibodies | 23 (1.4) | 1662 |
| Type of maintenance inhaler device, n (%) | ||
| Multiple-dose DPI | 935 (75.2) | 1244 |
| pMDI | 240 (19.3) | 1244 |
| Single-dose DPI | 26 (2.1) | 1244 |
| pMDI + multiple-dose DPI | 39 (3.1) | |
| pMDI + single-dose DPI | 4 (0.3) | 1244 |
DPI dry powder inhaler, FEV1 forced expiratory volume in 1 s, GINA Global Initiative for Asthma, PEF peak expiratory flow, pMDI pressurized metered-dose inhaler.
aPoorly controlled.